Unproven Autism Treatments Gain Traction Despite Safety Warnings
Approaching one year since new health leadership took office, questionable information from federal authorities regarding autism origins and interventions continues mounting.
In late 2025, the FDA discreetly removed online content addressing risks associated with a disputed autism therapy. Supporters of chelation therapy—including a prominent autism advisor who maintains discredited claims about the condition—assert it eliminates heavy metals from bloodstreams and can “cure” autism, notwithstanding scarce evidence and severe side effects. A five-year-old child’s death followed chelation therapy administration in 2005. Authorities indicated the content was “retired” with other materials.
Concurrently, two scientists authored a New England Journal of Medicine piece published Wednesday examining risks of broadening leucovorin application without appropriate safeguards. Senior health administrators promoted this cancer drug as a possible autism intervention in September, despite insufficient evidence demonstrating effectiveness. The scientists express concern about off-label prescribing at elevated doses that may remain in circulation for extended periods. Researchers lack understanding of how this impacts human physiology. Expanding leucovorin authorization requires comprehensive long-term effect studies, they maintain.
Federal Whole Milk Promotion Campaign
The administration’s social media effort urging Americans to #DrinkWholeMilk may appear surreal, yet U.S. authorities maintain an extensive record of advancing dairy consumption—sometimes with troubling associations.
Millennials readily recall the renowned “Got Milk?” initiative from the 1990s and 2000s featuring prominent figures sporting milk mustaches. What distinguishes this current push from the health secretary is highlighting whole milk specifically and direct government official participation in advertising.
Recently enacted legislation permits schools to offer whole milk following more than ten years’ menu absence, while updated dietary recommendations favor full-fat dairy versus nonfat and reduced-fat varieties. Even among products with influential advocacy groups and marketing programs, dairy occupies a distinctive position regarding explicit governmental support, experts observe.
>>>Read Vitamin D3 Shown to Protect Against Repeat Heart Attacks<<<
Broader Implications
These parallel developments reflect fundamental questions about evidence-based policymaking, commercial influence on health guidance, and federal responsibilities in protecting vulnerable populations.
The autism treatment promotions particularly concern medical professionals, as they involve therapies ranging from unproven to potentially harmful being endorsed or tacitly approved through regulatory silence. The chelation therapy webpage removal and leucovorin enthusiasm suggest policy priorities may not align with scientific consensus on autism intervention safety and efficacy.
Meanwhile, the whole milk campaign resurrects nutritional debates many believed settled, with full-fat dairy products receiving unprecedented direct government promotion despite decades of dietary guidance favoring lower-fat alternatives for cardiovascular health.
Together, these stories illuminate tensions between traditional evidence-based health policy and evolving federal approaches to medical guidance, raising questions about how these shifts will impact public health outcomes, particularly for children and other vulnerable groups.
What We Are Reading
Understanding Autism in Adults: Signs, Challenges, and Paths to Diagnosis